
Abivax announces new results on its flagship product obefazimod
(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in Copenhagen, Denmark. “We continue to be encouraged by the emerging clinical profile of obefazimod based on the 96-week efficacy and safety data from our Phase…